Navigation Links
Antibody in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... event profile was as anticipated for an anti-EGFR antibody in combination with oxaliplatin-based ... oxaliplatin-based chemotherapy and an anti-EGFR antibody are combined. "Our study underscores the ... leading to cancer progression. Anti-EGFR antibody therapies work by blocking the activation of ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... company developing a new rat-based human antibody platform, used Sangamo's ZFNs to knock out the ... immunoglobulin M (IgM), an important gene for rat antibody production. Inactivation of rat IgM expression ... of the paper. "Inactivation of endogenous rat antibody expression is essential for ...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

... of an adjuvant, and they raise not only strong antibody responses but robust cellular responses, both of ... dose-dependent hemagglutination inhibition ("HI") antibody responses. After just a single dose of the H1N1 vaccine, all vaccinated animals developed HI antibody levels considered to be protective. These ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... type 1 diabetes, is a humanized monoclonal antibody engineered to alter the function of the T ... set of capabilities in monoclonal antibody product development. The company's product ... lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune ...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

... entitled "Dose Ranging Studies of an Anti-CD3 antibody in NOD mice to Determine Minimum Effective Dose," ... dosing regimens of the anti-CD3 monoclonal antibody in a commonly used non-obese diabetic (NOD) mouse ... Otelixizumab is a novel monoclonal antibody being developed for the treatment of type 1 ...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... presented phase 2 clinical data of the BiTE(R) antibody blinatumomab (MT103) at the 14th Congress of the ... (MRD)(1). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out ... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma ... Germany. Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out ... treated with anti-CD19/-CD3 bispecific BiTE(R) antibody blinatumomab. 14th Congress of EHA, abstract ...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

... Valortim(R) is a fully human monoclonal antibody generated by Medarex, Inc's UltiMAb(R) technology ... Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known ... low as 1 mg/kg resulted in circulating levels of antibody after a month, with a similar potency for ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the ... loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. ... company focused on developing fully human antibody therapeutics for the potential treatment of ...

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338

... leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ... value by developing a diverse pipeline of antibody products to address the world's unmet healthcare ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... of cancer types. TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor ... By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide ... existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit ...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

... Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In ... exclusive option to in-license this monoclonal antibody and will thereafter assume responsibility for ... royalties on worldwide sales of marketed GSK antibody products aimed at OBT targets. Furthermore, OBT ...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

... when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe ... Rheumatoid Arthritis MDX-1100 is a fully human antibody that targets IP-10 (also known as CXCL-10), a ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

... using Affitech's unique MBAS (Molecule Based antibody Screening) method for selection and improvement ... tumor microenvironment, showing that the anti-PS antibody induced a sequential release of cytokines and ... efficiency and robustness of Affitech's range of antibody discovery platforms which include CBAS (Cell ...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

... areas of development across Micromet's BiTE antibody platform and included updates on: BiTE antibody Blinatumomab -- a rapid path to market has been ... in December. BiTE antibody MT110 -- data presented at this week's annual ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... -Treatment with Mouse Equivalent to the Human antibody Inhibited Tumor Growth in a Prostate Cancer Model ... is similar to Peregrine's lead clinical stage antibody bavituximab and extends Peregrine's anti-PS antibody pipeline. Bavituximab is in Phase II clinical ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

... of these cancer cells. In mice, daily EGFR BiTE antibody doses as low as 0.1 microgram/kilogram were ... active serum levels of the cetuximab-based BiTE antibody are tolerated. "The data show that our BiTE ... that the development of an EGFR-directed BiTE antibody for the treatment of patients with KRAS- and ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... Characterization of MDX-1338, a human anti-CXCR4 antibody proposed for therapeutic application in AML and ... Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model (Abstract #838) ... Efficacy and Toxicity of anti-mesothelin antibody drug conjugate (Abstract #3235) Mesothelin is ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... stimulating ability of a fully human anti-PS antibody and the other demonstrates the ability of a second fully human anti-PS antibody to stimulate development of a critical component ... anti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in Phase II clinical ...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

... humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen. ... humanized and deimmunized monoclonal antibody that targets the protective antigen of B. ... New Jersey, is focused on the development of antibody therapeutics for the treatment of ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

... cancers. IST has genetically engineered an antibody drug that binds specifically to a target protein ... called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous ...

AACR Data Highlights InNexus Preclinical Antibody Candidate

... Underscore Potency, Binding Capabilities for antibody Pipeline And Novel Technologies - ... into antibodies. The increased potency of the antibody resulting from this technique suggests a new way to enhance antibody performance." Jeff Morhet, Chairman and ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million ... Nycomed are developing MT203, a human anti-GM-CSF antibody that may be useful for the treatment of various ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary ...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... is a fully human anti-toxin monoclonal antibody being developed in conjunction with Medarex, Inc. ... Valortim(R) is a fully human monoclonal antibody designed to protect against and treat anthrax ... Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... phase 2 trial of its human anti-EpCAM IgG1 antibody adecatumumab (MT201) for the treatment of ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

... 1 clinical trials; IN-N01, a humanized monoclonal antibody designed to promote the clearance of soluble beta ... license to its ANTISENILIN(R) monoclonal antibody platform to Wyeth and Elan Pharma International ... and sale of Bapineuzumab, a monoclonal antibody intended to treat AD. Wyeth and Elan are ...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

... this study, the vaccine demonstrated strong HAI antibody titers against the H5N1 A/Indonesia strain. The ... The HA and NA are included to induce neutralizing antibody responses to prevent infection and spread of the ... "These data, coupled with the strong neutralizing antibody titer data from this study disclosed last year, ...

Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening

... infection, who would be missed by traditional HIV antibody tests, according to research presented by Johns ... from patients who subsequently tested HIV antibody positive were tested individually with two ... Combo assay and two third-generation HIV antibody tests. The Abbott combination assay ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... Topical Delivery of ESBA105, an Anti-TNF Alpha antibody Fragment in Patients Undergoing Cataract Surgery ... -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the ... from the surgery. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a major ...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

... delivery of 20,000 doses of its human monoclonal antibody drug ABthrax(TM) (raxibacumab) to the U.S. ... of anthrax. ABthrax is a human monoclonal antibody to Bacillus anthracis protective antigen that ... as part of its collaboration with Cambridge antibody Technology. Research has shown that protective ...

Cephalon Signs Option Agreement to Acquire Ception Therapeutics

... Promising Monoclonal antibody In Late- Stage Clinical Trial for the Treatment ... reslizumab. Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5) currently in a ... Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). IL-5 plays a ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the ... I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This ... of ESBA105 directly to the affected joint, the antibody fragment quickly and efficiently distributes to ...

Micromet Key Events for 2009

... Adecatumumab, an EpCAM-targeting human monoclonal antibody in development with Merck-Serono is expected to ... -- Blinatumomab, a CD19-targeting BiTE antibody in development with MedImmune, is expected to ... -- MT203, a GM-CSF neutralizing human monoclonal antibody in development with Nycomed for the treatment of ...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

... treated with a currently marketed EGFR-targeting antibody together with radiation while absent in patients ... the patients treated with other EGFR-targeting antibody drugs in combination with radiation while absent ... activity that rivals the other EGFR-targeting antibody drugs. Nimotuzumab is currently being ...

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

... of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 ... had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in ... virus strain, A/Vietnam/1203/04, also induced antibody responses against the H5N1 influenza virus ...

SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial

... was well-tolerated, and induced neutralizing antibody responses in 80% of the vaccinees and T-cell ... events were reported. SARS-specific neutralizing antibody responses were detected in 8 of 10 subjects. ... were detected in 2 of 10 subjects. Neutralizing antibody responses are important in preventing infection. ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the ... loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B cells.(4) This ... company focused on developing fully human antibody therapeutics for unmet medical needs. Using ...

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma

... of MDX-1401, a human anti-CD30 antibody with enhanced effector function, for therapy of ... is a non-fucosylated version of the MDX-060 antibody and is enhanced for greater antibody-dependent ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...

Micromet Expands Committed Equity Financing Facility to $75 Million

... The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ... of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets ...

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

... Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest ... to research and develop a fully human anti-PD-1 antibody for the treatment of cancer. The two companies ... MDX-1106/ONO-4538 is a novel fully human antibody designed to target and inhibit the function of ...
Other Contents
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/24/2014)... Over 700 toys, that’s what ... That is 700 smiling little faces this holiday that ... $6000 in monetary donations was given to the various ... expenses they incur through the year. Some of the ... Child's Haven , Shrine's Children's Hospitals, Toys for Tots ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 25, 2014 Today, UWDress.com, the famous women’s ... wedding gowns, and launched a site-wide wedding gown promotion. ... wedding gowns in a more unexpected way, the collection should ... popular in the global market, and they are available with ... are offered at discounted prices, up to 75% off; most ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering bamboo flooring ... announces its multiple layer bamboo panel board collection , ... , Bamboo panel is the product made from 100 ... board features high quality selective bamboo and eco-friendly adhesives ... panel consists of multiple layers of bamboo. , According ...
(Date:12/24/2014)... A new, injectable weight-loss drug has been approved by ... on Tuesday approved Saxenda (liraglutide) for adults who are ... at least one weight-related health condition, such as high ... Patients taking the drug, made by Novo Nordisk, should ... FDA noted. "Obesity is a public health concern ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
Other TagsOther Tags